ePharmaSolutions

epharmasolutions.com

We support the drug development industry with solutions that improve the identification, activation, training and management of clinical trial sites. With new perspectives on old problems, we deliver technology-enabled solutions that help to “un-complicate” the chaos of clinical trial management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

news image

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More

Business Insights

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

news image

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More

Research

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Regeneron | November 24, 2020

news image

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More

Pharma Tech

MEDABLE AND CVS HEALTH ANNOUNCE COLLABORATION TO EXPAND CLINICAL TRIAL ACCESS

Medable Inc. and CVS Health | February 08, 2022

news image

Medable Inc. and CVS Health announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic™ locations via Medable’s clinical trials software platform. CVS Health Clinical Trial Services™ will manage the relationship. The collaboration combines Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to effectively deliver clinical trials in a way that improves pa...

Read More
news image

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More
news image

Business Insights

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More
news image

Research

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Regeneron | November 24, 2020

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More
news image

Pharma Tech

MEDABLE AND CVS HEALTH ANNOUNCE COLLABORATION TO EXPAND CLINICAL TRIAL ACCESS

Medable Inc. and CVS Health | February 08, 2022

Medable Inc. and CVS Health announced a collaboration to expand clinical trial access and engagement for patients at select MinuteClinic™ locations via Medable’s clinical trials software platform. CVS Health Clinical Trial Services™ will manage the relationship. The collaboration combines Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to effectively deliver clinical trials in a way that improves pa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us